This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

1-24. (Canceled).

25. (Currently amended). A method of inhibiting an infection, comprising <u>administering to the</u> gastrointestinal tract of an animal contacting an infected site with <u>a composition comprising an isolated Bacillus</u> strain, wherein said strain produces more lysine aminopeptidase than <u>Bacillus</u> coagulans Hammer strain ATCC No. 31284 the composition of claim 1.



26. (Currently amended). A method of inhibiting an infection, comprising <u>administering to the gastrointestinal tract of an animal contacting an infected site with a composition comprising an isolated *Bacillus* strain, wherein said strain is selected from the group consisting of *Bacillus coagulans* GBI-1, *Bacillus coagulans* GBI-20, *Bacillus coagulans* GBI-30 and *Bacillus coagulans* GBI-40, or a combination thereof contacting an infected site with a *Bacillus coagulans* composition.</u>

27-28. (Cancelled).



- 29. (Original). The method of claim 26, wherein said composition comprises a viable vegetative bacterial cell.
- 30. (Original). The method of claim 26, wherein said composition comprises a bacterial spore.

31-32. (Cancelled).

33. (Original). The method of claim 29, wherein said composition is administered at a dose of  $1 \times 10^2$  to  $1 \times 10^{14}$  viable vegetative bacterial cells per day.



- 34. (Original). The method of claim 30, wherein said composition is administered at a dose of  $1 \times 10^2$  to  $1 \times 10^{14}$  spores per day.
- 35. (Currently amended). The method of claim 26, wherein said composition is administered orally, or buccally, topically, vaginally, nasally, ocularly, or otically.

## REMARKS